VERU INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)
VERU INC. (VERU) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) of -$19.00 thousand for the 6-month period ending 2024-03-31, per its 10-Q filed 2024-05-08.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease · last filed 2024-05-08
- VERU INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2024-03-31 was -$21.00K.
- VERU INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2023-12-31 was $2.00K, a 99.70% decline year-over-year.
- VERU INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2023-09-30 was -$644.00K.
- VERU INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2023-06-30 was -$1.79M.
- VERU INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2023 was -$2.96M.
- VERU INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2022 was -$3.56M, a 196.95% decline from fiscal 2021.
- VERU INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2021 was $3.67M, a 558.71% increase from fiscal 2020.
- VERU INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2020 was $557.00K, a 53.54% decline from fiscal 2019.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2024-03-31 | -$21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-08 | -$19.00K 10-Q · filed 2024-05-08 | -$663.00K derived: sum of 3 quarters · filed 2024-05-08 | -$2.45M derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | $2.00K 10-Q · filed 2024-04-01 | -$642.00K derived: sum of 2 quarters · filed 2024-04-01 | -$2.43M derived: sum of 3 quarters · filed 2024-04-01 | -$3.63M derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-09-30 | -$644.00K derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2024-04-01 | -$2.43M derived: sum of 2 quarters · filed 2024-04-01 | -$3.63M derived: sum of 3 quarters · filed 2024-05-08 | -$2.96M 10-K/A · filed 2024-04-01 |
| 2023-06-30 | -$1.79M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2023-11-15 | -$2.99M derived: sum of 2 quarters · filed 2024-05-08 | -$2.32M 10-Q/A · filed 2023-11-15 | -$6.43M derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-03-31 | -$1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-08 | -$530.00K 10-Q · filed 2024-05-08 | -$4.64M derived: sum of 3 quarters · filed 2024-05-08 | -$5.53M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $670.00K 10-Q · filed 2024-04-01 | -$3.44M derived: sum of 2 quarters · filed 2024-04-01 | -$4.33M derived: sum of 3 quarters · filed 2024-04-01 | -$3.10M derived: sum of 4 quarters · filed 2024-04-01 |
| 2022-09-30 | -$4.11M derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2024-04-01 | -$5.00M derived: sum of 2 quarters · filed 2024-04-01 | -$3.77M derived: sum of 3 quarters · filed 2024-04-01 | -$3.56M 10-K/A · filed 2024-04-01 |
| 2022-06-30 | -$881.00K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2023-11-15 | $348.00K derived: sum of 2 quarters · filed 2023-11-15 | $557.00K 10-Q/A · filed 2023-11-15 | $2.20M derived: sum of 4 quarters · filed 2023-11-15 |
| 2022-03-31 | $1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-11 | $1.44M 10-Q · filed 2023-05-11 | $3.08M derived: sum of 3 quarters · filed 2023-05-11 | $4.45M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $209.00K 10-Q · filed 2023-02-09 | $1.85M derived: sum of 2 quarters · filed 2023-02-09 | $3.22M derived: sum of 3 quarters · filed 2023-02-09 | $3.27M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-09-30 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-05 | $3.01M derived: sum of 2 quarters · filed 2022-12-05 | $3.06M derived: sum of 3 quarters · filed 2022-12-05 | $3.67M 10-K · filed 2022-12-05 |
| 2021-06-30 | $1.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-11 | $1.43M derived: sum of 2 quarters · filed 2022-08-11 | $2.03M 10-Q · filed 2022-08-11 | $2.49M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $53.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-12 | $657.00K 10-Q · filed 2022-05-12 | $1.12M derived: sum of 3 quarters · filed 2022-05-12 | $1.29M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $604.00K 10-Q · filed 2022-02-09 | $1.07M derived: sum of 2 quarters · filed 2022-02-09 | $1.24M derived: sum of 3 quarters · filed 2022-02-09 | $767.00K derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-09-30 | $463.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-02 | $632.00K derived: sum of 2 quarters · filed 2021-12-02 | $163.00K derived: sum of 3 quarters · filed 2021-12-02 | $557.00K 10-K · filed 2021-12-02 |
| 2020-06-30 | $169.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-12 | -$300.00K derived: sum of 2 quarters · filed 2021-08-12 | $94.00K 10-Q · filed 2021-08-12 | $1.05M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$469.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-12 | -$75.00K 10-Q · filed 2021-05-12 | $878.00K derived: sum of 3 quarters · filed 2021-05-12 | $721.00K derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $394.00K 10-Q · filed 2021-02-10 | $1.35M derived: sum of 2 quarters · filed 2021-02-10 | $1.19M derived: sum of 3 quarters · filed 2021-02-10 | $1.82M derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-09-30 | $953.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-10 | $796.00K derived: sum of 2 quarters · filed 2020-12-10 | $1.42M derived: sum of 3 quarters · filed 2020-12-10 | $1.20M 10-K · filed 2020-12-10 |
| 2019-06-30 | -$157.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-13 | $471.00K derived: sum of 2 quarters · filed 2020-08-13 | $246.00K 10-Q · filed 2020-08-13 | -$1.05M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $628.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-13 | $403.00K 10-Q · filed 2020-05-13 | -$889.00K derived: sum of 3 quarters · filed 2020-05-13 | -$511.00K derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | -$225.00K 10-Q · filed 2020-02-12 | -$1.52M derived: sum of 2 quarters · filed 2020-02-12 | -$1.14M derived: sum of 3 quarters · filed 2020-02-12 | |
| 2018-09-30 | -$1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-12 | -$914.00K derived: sum of 2 quarters · filed 2019-12-12 | -$893.00K 10-K · filed 2019-12-12 | |
| 2018-06-30 | $378.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-08 | $399.00K 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $21.00K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |